Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records

Main Article Content

Paul Yamauchi
Chi-Chang Chen
Yao Ding
et al.



Abstract not available.


Disclosures: Study sponsored by Novartis.

Most read articles by the same author(s)

1 2 3 > >>